SWOG clinical trial number
CTSU/A041202
A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia(CLL)
Closed
Phase
Abbreviated Title
Rand PIII Bendamustine/Rituximab vs. Ibrutinib/Rituximab vs. Ibrutinib for Untreated AML >/= 65
Status Notes
EFFECTIVE MONDAY, May 16, 2016 at 4:30 pm ET, A041202 will permanently close to new patient registration (Step 1).
Patients on treatment should continue to be treated and followed as required per protocol. Patients on Arm 1 who progress and who wish to crossover to receive ibrutinib alone will still be able to do so. Re-registration (Step 2) will remain open for crossover patients.
A registration closure notice will be included in the May 1, 2016 Alliance protocol posting and on the Alliance A041202 study page on the CTSU Web site thereafter.
Effective 12/28/15, A041202 permanently closed to new patient pre-registration (Step 0).
Questions may be directed to Samantha Sublett at ssublett@uchicago.edu or 773-834-4091
Patients on treatment should continue to be treated and followed as required per protocol. Patients on Arm 1 who progress and who wish to crossover to receive ibrutinib alone will still be able to do so. Re-registration (Step 2) will remain open for crossover patients.
A registration closure notice will be included in the May 1, 2016 Alliance protocol posting and on the Alliance A041202 study page on the CTSU Web site thereafter.
Effective 12/28/15, A041202 permanently closed to new patient pre-registration (Step 0).
Questions may be directed to Samantha Sublett at ssublett@uchicago.edu or 773-834-4091
Activated
12/15/2013
Closed
12/28/2015
Participants
Research committees
Leukemia
Treatment
Rituximab
Bendamustine
Ibrutinib
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Publication Information Expand/Collapse
2024
2023
2021
PMid: PMID34274940 | PMC number: PMC8744070
2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
PMid: PMID30501481 | PMC number: PMC6325637
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A042001
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
49%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open